Renoprotective effects of azelnidipine in hypertensive diabetic patients in Mie

Trial Profile

Renoprotective effects of azelnidipine in hypertensive diabetic patients in Mie

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Azelnidipine (Primary) ; Trichlormethiazide (Primary) ; Amlodipine; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms RANDAM
  • Most Recent Events

    • 04 Oct 2012 Primary endpoint 'Urinary-albumin:creatinine-ratio' has been met.
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
    • 06 Apr 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top